Sector News

Novo Nordisk joins pharma’s IPO clique with plans for tech subsidiary spinoff

February 10, 2015
Life sciences
It’s official: Novo Nordisk has joined the spinoff club. The Danish drugmaker says it’s ready to let its information technology unit, NNIT, go solo via an initial public offering.
Few details are available at the moment; Novo Nordisk announced the decision in a bare-bones press release. The company says it will take place in 4-5 weeks, but won’t say how big the offering might be. What’s certain is that it’s another example of a drugmaker sharpening its focus by hiving off subsidiaries and business units.
Novo has been weighing the prospect since last January, when the company named a new CFO for NNIT, Carsten Krogsgaard Thomsen, and charged him with reviewing a spinoff. In March, Novo hired Morgan Stanley and Danske Bank to advise on the potential offering. The questions were the usual ones: Could hiving off NNIT “create value”? Would NNIT be better off on its own?
Independence might make it easier for NNIT to compete for clients. NNIT brought in about 2.2 billion kroner in 2013, or about $404 million, and external customers have accounted for an increasing share of those sales. For 2014, that share was expected to be about 50%. That’s one reason why Novo was looking at a stock offering, Thomsen said last year.
“An IPO will provide the company with improved access to the capital markets and stronger brand recognition, among other benefits,” NNIT said in a separate press release (as quoted by Reuters).
The IT unit has been edging its way toward solo status for years. Novo Nordisk formally set NNIT aside in an independent, wholly owned subsidiary back in 1998. Last year’s sales amounted to 2.4 billion kroner.
Novo’s is the second spinoff announcement so far this year. Last week, GlaxoSmithKline said it was moving toward an IPO for its HIV joint venture, ViiV Healthcare, and would decide for certain by midyear. That would be a much bigger deal; with its £1.5 billion in 2014 sales, analysts see ViiV valued at £12 billion to £18 billion ($18 billion to $27 billion). 
By Tracy Staton

Related News

September 25, 2020

Novo Nordisk tees up phase 3 trial for once-weekly insulin

Life sciences

People with Type 2 diabetes are no strangers to needles, with some injecting bolus insulin after meals, others injecting basal insulin once or twice a day, and others still doing […]

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]